Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangsu Hengrui Pharmaceuticals Co EV-to-OCF?
Jiangsu Hengrui Pharmaceuticals CoJHPCY 70 EV-to-OCF is 47.85 as of Aug. 26, 2026, which is 36% below its 10-year median of 74.58. GuruFocus rates JHPCY with a GF Score™ of 70/100 and a GF Value™ of $24.69 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks worse than 79.1% on this metric.
JHPCY'
s EV-to-OCF Range Over the Past 10 Years
Min: 24.07 Med: 74.58 Max: 256.55
Current: 30.11
During the past 13 years, the highest EV-to-OCF of Jiangsu Hengrui Pharmaceuticals Co was 256.55. The lowest was 24.07. And the median was 74.58.
JHPCY's EV-to-OCF is ranked worse than 79.1% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.6
vs JHPCY: 30.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Hengrui Pharmaceuticals Co (OTCPK:JHPCY) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Hengrui Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Hengrui Pharmaceuticals Co's share price for today is $20.00.
Jiangsu Hengrui Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.334.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jiangsu Hengrui Pharmaceuticals Co EV-to-OCF Related Terms
Jiangsu Hengrui Pharmaceuticals Co EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co EV-to-OCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF falls into.
Jiangsu Hengrui Pharmaceuticals Co's current Enterprise Value is $60,680 Mil.
Jiangsu Hengrui Pharmaceuticals Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (JHPCY) has a EV-to-OCF of 47.85 as of Aug. 26, 2026. This is 36% below median its historical median of 74.58. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF has ranged from 24.07 to 256.55. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #795 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 79.1%.
Is Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF too high?
Jiangsu Hengrui Pharmaceuticals Co's current EV-to-OCF of 47.85 is 36% below median its 10-year median of 74.58. Over the past 10 years, this metric has ranged from a low of 24.07 to a high of 256.55. The Drug Manufacturers industry median EV-to-OCF is 10.60. Jiangsu Hengrui Pharmaceuticals Co's value of 47.85 is 351.4% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #795 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #795 out of 1005 companies for EV-to-OCF. This places Jiangsu Hengrui Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-OCF is 10.60. Jiangsu Hengrui Pharmaceuticals Co's value of 47.85 is 351.4% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own EV-to-OCF has ranged from 24.07 to 256.55 over the past decade. While the company's 10-year median is 74.58 vs. the industry median of 10.60, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current EV-to-OCF of 47.85 is 351.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current EV-to-OCF is 47.85, which is 36% below median its own 10-year median of 74.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (JHPCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.69, compared to a current price of $20.00 — trading 19% below its estimated fair value. The current EV-to-OCF is 47.85, which is 36% below median its 10-year median of 74.58 and 351.4% above the Drug Manufacturers industry median of 10.60. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (JHPCY), the current EV-to-OCF is 47.85 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $20.00 is trading 19% below its estimated GF Value™ of $24.69.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for JHPCY:
EV-to-OCF: 47.85 (36% below median its 10-year median of 74.58)
GF Value™: $24.69 vs. price of $20.00 (19% below fair value)
Industry Position: 351.4% above the Drug Manufacturers median (#795 of 1005)
No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
70GF Score
Get the complete analysis for JHPCY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JHPCY has been successfully added to your 
